Telaprevir (VX-950), marketed under the brand names Incivek and Incivo, is a pharmaceutical drug for the treatment of hepatitis C co-developed by Vertex Pharmaceuticals and Johnson & Johnson. It is a member of a class of antiviral drugs known as protease inhibitors. Specifically, telaprevir inhibits the hepatitis C viral enzyme NS3.4A serine protease. Telaprevir is only indicated for use against hepatitis c genotype 1 viral infections and hasn´t been proven to have an effect on or being safe when used for other genotypes of the virus. The standard therapy of pegylated interferon and ribavirin is less effective on genotype 1 and telaprevir offers a welcome addition to the treatment of this genotype.

Read more about TelaprevirClinical Trials and Approvals, Adverse Effects

Other articles related to "telaprevir":

Telaprevir - Adverse Effects
... anemia and leukopenia/neutropenia) were more frequent in the telaprevir groups than in the control group (37% vs ... it would add a “Black Box” warning of possible side effects on the US labels of telaprevir, following "reports of a small number of fatal skin reactions in patients ...
Vertex Pharmaceuticals - Telaprevir
... Development and commercialization of telaprevir is shared with Johnson Johnson for European distribution and Mitsubishi for Asia ... Telaprevir is a protease inhibitor ...